Salarius Pharmaceuticals, Inc. (SLRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Salarius Pharmaceuticals reported revenue of $0. Net income was -$12.5M, or -$129.10 per diluted share. Operating activities generated -$4.8M of cash, leaving -$5.4M of free cash flow. At fiscal year end, Salarius Pharmaceuticals held $11.1M in total assets against $5.2M in total liabilities, including $10.7M of cash and equivalents.
Open the full interactive Salarius Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Salarius Pharmaceuticals Key Stats
| Share Price | $1.24 |
|---|---|
| Market Cap | $659,640 |
| 52-Week Range | $1.24 – $55.20 |
| Shares Outstanding | 531,968 (basic, 2026 Q2) |
Salarius Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $5.2M | $1.8M | $0 | $0 | $0 | $0 |
| Operating Income | -$7.8M | -$12.8M | -$31.8M | -$12.9M | -$5.7M | -$12.6M |
| Pre-Tax Income | -$7.4M | -$12.8M | -$31.6M | -$12.5M | -$5.6M | -$12.5M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$7.4M | -$12.8M | -$31.6M | -$12.5M | -$5.6M | -$12.5M |
| Diluted EPS | -$18000.00 | -$11160.00 | -$21427.20 | -$5529.60 | -$1042.20 | -$129.10 |
Salarius Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $227,629 |
| Net Income | -$873,467 | -$9.0M | -$2.2M | -$2.4M |
| Diluted EPS | -$21.72 | -$92.58 | -$4.18 | -$4.46 |
Salarius Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.1M | $29.2M | $12.1M | $5.9M | $2.4M | $10.7M |
| Current Assets | $15.8M | $30.2M | $14.5M | $6.5M | $3.0M | $11.0M |
| Total Assets | $24.9M | $40.8M | $14.7M | $6.6M | $3.0M | $11.1M |
| Current Liabilities | — | — | — | — | — | $5.2M |
| Total Liabilities | $2.8M | $2.1M | $4.3M | $1.3M | $1.5M | $5.2M |
| Shareholders' Equity | $22.2M | $38.7M | $10.4M | $5.3M | $1.5M | $5.9M |
Salarius Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$10.3M | -$10.2M | -$17.6M | -$12.8M | -$4.5M | -$4.8M |
| Cash From Investing | -$2,600 | $0 | -$1.5M | $0 | — | $764,735 |
| Cash From Financing | $17.7M | $28.3M | $2.0M | $6.6M | $1.1M | $12.3M |
| Free Cash Flow | -$10.3M | -$10.2M | — | — | — | -$5.4M |
| Dividends Paid | $0 | — | — | — | — | — |
Figures from Salarius Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Salarius Pharmaceuticals financials page for every line item.
Salarius Pharmaceuticals Company Profile
| Ticker | SLRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Houston, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001615219 |
Frequently Asked Questions
What was Salarius Pharmaceuticals' revenue in fiscal 2025?
Salarius Pharmaceuticals (SLRX) reported revenue of $0 for fiscal 2025.
What is Salarius Pharmaceuticals' annual revenue history?
Salarius Pharmaceuticals' annual revenue by fiscal year: 2020: $5.2M; 2021: $1.8M; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Salarius Pharmaceuticals' net income in fiscal 2025?
Salarius Pharmaceuticals reported net income of -$12.5M for fiscal 2025.
What was Salarius Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Salarius Pharmaceuticals' diluted EPS was -$129.10 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Salarius Pharmaceuticals generate in fiscal 2025?
Salarius Pharmaceuticals generated -$5.4M of free cash flow in fiscal 2025.
What was Salarius Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Salarius Pharmaceuticals reported revenue of $227,629.
How many shares of Salarius Pharmaceuticals are outstanding?
Salarius Pharmaceuticals reported a weighted average of 531,968 basic shares outstanding in 2026 Q2.
What is Salarius Pharmaceuticals' market cap?
Based on its latest closing price, Salarius Pharmaceuticals (SLRX) has a market capitalization of about $659,640.
When does Salarius Pharmaceuticals' fiscal year end?
Salarius Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Salarius Pharmaceuticals headquartered?
Salarius Pharmaceuticals lists its business address in Houston, Texas in its SEC filings.